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Abstract
Importance
Irritable bowel syndrome (IBS) is associated with significant morbidity in children and ado-
lescents, and the therapeutic efficacy of available treatment options is limited. The role of
vitamin D supplementation in pediatric IBS is unclear as the vitamin D status of pediatric
patients with IBS is unknown. Equally, the relationship of vitamin D status with psychoso-
matic symptoms in children and adolescents is unclear.
Aim
To characterize the vitamin D status of pediatric patients with IBS using a case-control study
design.
Hypothesis
Serum 25-hydroxyvitamin D [25(OH)D] concentration will be similar between patients with
IBS and controls.
Subjects and methods
A retrospective case-controlled study of 116 controls (age 14.6 ± 4.3 y), female (n = 67;
58%) and 55 subjects with IBS (age 16.5 ± 3.1y), female (n = 44; 80%). Overweight was
defined as BMI of85th but <95th percentile, and obesity as BMI95th percentile. Vitamin D
deficiency was defined as 25(OH)D of <50 nmol/L, while seasons of vitamin D draw were
categorized as summer, winter, spring, and fall. Major psychosomatic manifestations
included in the analysis were depression, anxiety, and migraine.
Results
More than 50% of IBS subjects had vitamin D deficiency at a cut-off point of <50 nmol/L
(53% vs. 27%, p = 0.001); and >90% of IBS subjects had vitamin D deficiency at a cut-off
point of <75 nmol/L (93% vs. 75%, p = 0.006). IBS subjects had significantly lower mean
25(OH)D: 53.2 ± 15.8 nmol/L vs. 65.2 ± 28.0 nmol/L, p = 0.003; and albumin: 6.2 ± 0.6 vs.
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6.5 ± 0.6 μmol/L, p = 0.0.01. IBS subjects with migraine had significantly lower mean 25
(OH)D concentration compared to controls (p = 0.01). BMI z-score was similar between the
controls and IBS subjects (0.5 ± 1.4 vs. 1.2 ± 2.9, p = 0.11).
Conclusions
Pediatric patients with IBS had significantly lower 25(OH)D concentration compared to con-
trols despite having similar mean BMI values as controls. Only 7% of the children and ado-
lescents with IBS were vitamin D sufficient, and >50% of the subjects with IBS had vitamin D
deficiency. This is a much higher prevalence of vitamin D deficiency compared to IBD and
other malabsorption syndromes. Monitoring for vitamin D deficiency should be part of the
routine care for patients with IBS. Randomized control trials are warranted to determine the
role of adjunctive vitamin D therapy in pediatric IBS.
Introduction
The vitamin D status of children and adolescents with irritable bowel disease (IBS) is not
known, and the relationship of vitamin D status with associated psychosomatic symptomatol-
ogy in IBS is unclear. Irritable bowel syndrome (IBS) is a non-inflammatory, functional disor-
der of the gastrointestinal tract that affects 10–15% of people in the industrialized world[1].
The pathogenesis of IBS remains an enigma and the mechanism responsible for the flares and
associated psychosomatic manifestations such as depression, anxiety, and migraines, are
poorly understood[2]. The etiopathogenesis of IBS is multifactorial and is believed to involve
the dysfunction of the brain-gut axis, enteric neuromuscular system, nonspecific immune acti-
vation, and altered intraluminal environment[2].
Adult subjects with IBS have a high prevalence of vitamin D deficiency[3] and vitamin D
supplementation is reported to be associated with improvements in various quality of life indi-
ces in these patients[2, 4]. This is crucial as the therapeutic efficacy of drugs used to manage
IBS is limited and the response to these agents vary between patients[5].
Regrettably, the vitamin D status of children and adolescents with IBS has not been charac-
terized, and the non-dietary determinants of vitamin D in this population are not fully
described. Equally, the relationship between vitamin D status and psychosomatic symptom-
atology in pediatric patients with IBS is not clear.
Additionally, there has not been a rigorous comparison of vitamin D status in children and
adolescents with either inflammatory bowel disease (IBD) or irritable bowel syndrome (IBS),
as these two disease states are easily confused with each other. This is important as our group
has previously characterized the vitamin D status in IBD and found no significant difference in
mean serum 25(OH)D concentration between children and adolescents with IBD and controls
[6]. However, we noted that IBD subjects with elevated erythrocyte sedimentation rate (ESR)
had significantly lower 25(OH)D concentration than controls which led to the recommenda-
tion that IBD subjects with elevated ESR should be monitored for vitamin D deficiency[6].
To address the above knowledge gap and help clear the confusion on vitamin D status in
IBD and IBS, we designed this study to determine the vitamin D status of pediatric patients
with IBS only; characterize the determinants of vitamin D status in this condition, and investi-
gate the relationship between vitamin D status and psychosomatic manifestations in IBS. We
hypothesized that vitamin D status would be similar in pediatric patients with IBS and controls.
Vitamin D status in irritable bowel syndrome
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Subjects and methods
Ethics statement
This study protocol was approved by the Institutional Review Board of the University of Mas-
sachusetts which granted the approval for the retrospective review of records from patients’
case records. Subjects’ data were anonymized and de-identified before analysis.
Subjects
This study involved the extraction and review of medical records of pediatric patients of ages
6–21 years with a confirmed diagnosis of IBS between January 1, 2007 and June 30, 2013 at the
Children’s Medical Center Database of the UMassMemorial Medical Center, Worcester, Mas-
sachusetts, USA.
Study subjects (n = 55; 11 males) were included if they had a confirmed diagnosis of IBS.
The diagnosis of IBS was established using the Rome 3 Criteria as follows: recurrent abdominal
pain or discomfort for at least 3 days per month in the preceding 3 months, and associated
with two or more of the following: (a) symptomatic improvement with defecation, (b) onset
associated with a change in frequency of stool, and (c) onset associated with a change in the
form or appearance of stool[7, 8]. Medical records were further reviewed for confirmed diag-
nosis of classic comorbidities of IBS: anxiety disorder, depression, and migraine headache.
Laboratory analytes including serum 25(OH)D, alanine transaminase (ALT), albumin, and
erythrocyte sedimentation rate (ESR) were available for all subjects, and were drawn on the
same day during routine clinic visit.
As described in detail previously[6, 9], the control group (n = 116; 67 females) consisted of
a cohort of healthy children and adolescents attending the well-child clinic of the Children’s
Medical Center. The controls were selected randomly through a systematic sampling scheme,
that involved the alphabetization of the list of the control subjects, and then selecting every 5th
individual for inclusion in the study. None of the control subjects had a diagnosis of IBS, IBD,
or celiac disease. The controls were neither receiving vitamin D supplementation nor steroid
therapy at the time of their inclusion in the study. The control subjects had serum 25(OH)D,
ALT, and albumin drawn as part of routine comprehensive metabolic panel and vitamin D
estimation during a clinic visit between January 1, 2007 and June 30, 2013.
The exclusion criteria for this study included pregnant or lactating subjects, patients with
chronic liver disease, malabsorption syndrome, chronic liver disease, IBD, diseases affecting
calcium and/or vitamin D metabolism, and any treatment with steroids, vitamin D or calcium
supplementation prior to the date of 25(OH)D measurement. Of the 65 subjects with IBS who
met the inclusion criteria, 10 subjects were excluded based on the aforementioned exclusion
criteria. Fifty-five subjects were included in the analysis.
The date of 25(OH)D measurement was used to determine the age of study subjects; and
the duration of disease was designated as the interval between the diagnosis of IBS and the
date of first 25(OH)D estimation. Seasonal variations in serum 25(OH)D concentration was
taken into consideration by categorizing subjects’ date of vitamin D drawn according to the
season as follows: summer (June 22-September 21), fall (September 22 –December 21), winter
(December 22- March 21), and spring (March 22 –June 21)[10].
Anthropometry
As described in detail previously[6, 9], weight was measured to the nearest 0.1 kg using an
upright scale. Height was measured to the nearest 0.1 cm using a wall-mounted stadiometer
that was calibrated daily. BMI was calculated from the formula: weight/height2 (kg/m2), and
Vitamin D status in irritable bowel syndrome
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expressed as standard deviation score (SDS) for age and sex, based on National Center for
Health Statistics (NCHS) data.[11] Overweight was defined as BMI of85th but<95th percen-
tile, and obesity was defined as BMI of95th percentile for age and gender.
Assays
Assay protocol has been previously described[6, 9]. Briefly, serum 25(OH)D concentration
was analyzed using 25-hydroxy chemiluminescent immunoassay (DiaSorin Liaison; Stillwater,
Minnesota), which measures total serum 25(OH)D content as it detects both metabolites of 25
(OH)D: 25(OH)D2 and 25(OH)D3. It has an intra- and inter-assay coefficients of variation of
5% and 8.2% respectively, and a functional sensitivity of 10 nmol/L. The characterization
of vitamin D status for this study was based on The Endocrine Society Clinical Practice Guide-
line which defined vitamin D status using serum 25(OH)D values as follows: vitamin D
deficiency < 20 ng/mL (50 nmol/L), insufficiency 20–29.9 ng/mL (50–74.5 nmol/L), and
sufficiency 30 ng/mL (75 nmol/L)[12]. This characterization is similar to the classification
of vitamin D status by the Institutes of Medicine and the American Academy of Pediatrics
which denote vitamin D deficiency as 25(OH)D <50 nmol/L; or sufficiency, 25(OH)D >50
nmol/L[13, 14].
ESR analyzer, Vesmatic 20 (Clinical Data, Inc., Smithfield, RI) was used to quantify ESR
according to standard protocol. Beckman Coulter AU System ALT procedure (Beckman Coul-
ter, Inc., 250 S. Kraemer Blvd. Brea, CA 92821, USA) was used to measure ALT, while albumin
concentrations were measured in a Roche/Hitachi 917 chemistry analyzer (Roche Diagnostic
Corporation, Indianapolis, IN) according to standard protocol.
Statistical analyses
Means and standard deviations (SD) were calculated for descriptive summary statistics and 25
(OH)D measurements. Univariate and multivariate comparisons on anthropometrics, 25(OH)
D, and other variables were conducted using ANOVA and two-tailed student’s t-test respec-
tively. Height, weight, and BMI data were expressed as z-scores. Race, gender proportionality,
and seasons of blood draw were compared using Pearson Chi-Square. Simple and multiple lin-
ear regression models, describing the relationships between anthropometric and biochemical
parameters, were specified. Data were expressed as mean ± SD. All statistical analyses were
performed using the SPSS Predictive Analytics SoftWare v.23 (IBM Corporation, Armonk,
NY).
Results
Comparison of the characteristics of subjects with IBS vs. controls
There were no differences in height SDS, weight SDS, and BMI SDS between the controls and
IBS subjects (Table 1). There were equally no differences in racial composition of subjects and
controls, and the season of 25(OH)D measurement. Subjects with IBS were older (p = 0.004),
had lower serum concentration of albumin (p = 0.01), and a significantly higher prevalence of
vitamin D deficiency at a cutoff point of50 nmol/L (53% vs. 27%, p = 0.001). Only 7% of IBS
patients met the criterion for vitamin D sufficiency, 25(OH)D of75 nmol/L, compared to
25% of controls (p = 0.006). The control group consisted of 75% Non-Hispanic Whites
(NHW), while the IBS cohort consisted of 78% NHW (p = 0.65).
Vitamin D status in irritable bowel syndrome
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The effect of BMI on serum 25(OH)D concentration in IBS vs. controls
When subjects were stratified into normal-weight (BMI <85th percentile) and overweight/
obese (BMI >85th percentile), serum 25(OH)D concentration was significantly higher in the
normal-weight controls compared to the overweight/obese controls (69.8 ± 27.5 nmol/L vs.
58.3 ± 27.6, p = 0.03), and to both the normal-weight and overweight/obese IBS subjects.
Serum 25(OH)D concentration was similar between the normal-weight IBS- and overweight/
obese IBS subjects (p = 0.91) (Fig 1). The normal-weight IBS subjects had lower 25(OH)D
concentration compared to the normal-weight controls (55.4 ± 17.5 vs. 69.8 ± 27.5 nmol/L,
p = 0.05), while normal-weight controls had significant higher 25(OH)D concentration com-
pared to the overweight/obese IBS patients (69.8 ± 27.5 nmol/L vs. 51.1 ± 14.0, p = 0.004).
The relationship between psychosomatic symptoms and 25(OH)D
concentration in IBS
Fig 2 shows the comparison of the 25(OH)D concentrations between the controls, IBS subjects
with anxiety (n = 17), IBS subjects with depression (n = 14), and IBS subjects with migraines
(n = 13). There was a significant difference in serum 25(OH)D between the 4 groups
(ANOVA, p = 0.004). Post hoc analysis revealed a significant difference in 25(OH)D between
the controls and subjects with IBS and migraines (p = 0.01), but not for IBS patients with
depression (p = 0.08), or IBS patients with anxiety (p = 0.44).
Regression analysis of 25(OH)D vs. ESR, albumin, and alanine
transaminase
A regression analysis of the IBS cohort showed no significant relationship between 25(OH)D
and ESR (R2 = 0.03, β = -0.05, p = 0.31), ALT (R2 = 0.043, β = 0.006, p = 0.94) and albumin
(R2 = 0.046, β = 0.057, p = 0.92) after adjusting for age, gender, race, season, and BMI SDS.
Seasons and 25(OH)D concentration in controls and IBD subjects
Fig 3 shows the relationship between seasons and serum 25(OH)D concentration in patients
with IBS and controls. There were significant differences in 25(OH)D concentrations between
Table 1. A comparison of the characteristics of subjects with irritable bowel syndrome and controls.
Parameter IBS (n = 55) Controls (n = 116) p value
Age (years) 17 ± 3 15 ± 4 0.004
Height SDS -0.2 ± 1 0.0 ± 1 0.39
Weight SDS 0.7 ± 1 0.4 ± 2 0.27
BMI SDS 1 ± 3 0.5 ± 1 0.11
Sex: (% Males) 20 42 0.004
Race (% White) 78 75 0.65
ALB (μmol/L) 6 ± 1 7 ± 1 0.01
ALT (U/L) 19 ± 20 19 ± 33 0.98
25(OH)D (nmol/L) 53 ± 16 65 ± 28 0.003
25(OH)D50 nmol/L (%) 53 27 0.001
25(OH)D75 nmol/L (%) 93 75 0.006
Seasons: (Summer-Fall, %) 47 56 0.28
IBS irritable bowel syndrome; SDS standard deviation score; 25(OH)D 25-hydroxyvitamin D; ALT alanine
transaminase; ALB albumin, significant p values are bolded.
doi:10.1371/journal.pone.0172183.t001
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the seasons (ANOVA, p = 0.04), with higher 25(OH)D concentration noted in the summer
than in winter in both the controls and IBS subjects. Serum 25(OH)D was significantly lower
in the subjects with IBS compared to controls (ANOVA, p = 0.04). There were no interactions
between the groups and seasons (ANOVA, p = 0.24).
Patient’s sex and 25(OH)D concentration
Analysis of the differences in 25(OH)D by sex between the controls and the IBS subjects
showed no difference in 25(OH)D between the male and female groups (ANOVA, p = 0.42).
Female controls, however, had a significantly higher 25(OH)D than female IBS subjects
(p = 0.002) while 25(OH)D was similar between the male controls and male IBS subjects
(p = 0.18). There was no difference between serum 25(OH)D concentration between the male
and female patients with IBS: 52.3 ± 7.2 nmol/L vs. 53.5 ± 7.3 nmol/L, (p = 0.85).
Race/Ethnicity and 25(OH)D concentration
When subjects were divided into non-Hispanic whites (NHW) and non-whites, the NHW
controls (n = 87) had significantly higher 25(OH)D concentration than NHW IBS subjects
(n = 43) (68.7 ± 24.8 vs. 54.7 ± 15.8 nmol/L, p<0.001), while 25(OH)D concentration was sim-
ilar between the non-white controls (n = 29) vs. non-white IBS subjects (n = 12) (55.3 ± 34.3
vs. 47.9 ± 15.2, p = 0.35).
Fig 1. Box plot of the comparison of 25-hydroxyvitamin D values of patients with irritable bowel
syndrome (IBS) and controls stratified by body mass index (BMI). This figure shows that serum 25(OH)D
concentration was significantly higher in the normal-weight controls compared to the overweight/obese
controls (69.8 ± 27.5 nmol/L vs. 58.3 ± 27.6, p = 0.03), and to both the normal-weight and overweight/obese
IBS subjects. Serum 25(OH)D concentration was similar between the normal-weight IBS- and overweight/
obese IBS subjects (p = 0.91) Note: 50 nmol/L = 20 ng/mL. Circles represent standard deviations.
doi:10.1371/journal.pone.0172183.g001
Vitamin D status in irritable bowel syndrome
PLOS ONE | DOI:10.1371/journal.pone.0172183 February 13, 2017 6 / 14
The response of IBS subjects to vitamin D supplementation
Fig 4 shows the change in serum 25(OH)D concentration in 13 subjects with IBS who received
vitamin D supplementation using either ergocalciferol or cholecalciferol of doses of 1000 IU to
4000 IU per day, and were monitored over a 9-month period. In the first 3 months of treat-
ment, there was a significant increase in 25(OH)D concentration from 45.4 ± 14.4 nmol/L to
68.8 ± 14.4 nmol/L, (p = 0.002). This response was maintained through the 9-month duration
of monitoring.
Discussion
This is the first study to characterize the vitamin D status of children and adolescents with IBS.
The primary finding from this study is that 1 out of every 2 pediatric patients with IBS has
vitamin D deficiency compared to 1 out of every 4 healthy children and adolescents without
IBS. Additionally, only 7% of subjects with IBS had vitamin D sufficiency compared to 25% of
Fig 2. Boxplot of the comparison of 25(OH)D concentrations between the controls and IBS subjects
with psychosomatic manifestations. This figure shows a significant difference in serum 25(OH)D between
the 4 groups: IBS subjects with anxiety (n = 17), IBS subjects with depression (n = 14), and IBS subjects with
migraines (n = 13), and the controls, (ANOVA, p = 0.004). Post hoc analysis revealed a significant difference
in 25(OH)D between the controls and subjects with IBS and migraines (p = 0.01), but not for IBS patients with
depression (p = 0.08), or IBS patients with anxiety (p = 0.44). Hatched boxes represent subjects with
symptoms, while clear boxes represent subjects with no symptoms. Circles and asterisks represent standard
deviations.
doi:10.1371/journal.pone.0172183.g002
Vitamin D status in irritable bowel syndrome
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controls. This is particularly striking as BMI SDS was similar for both the IBS subjects and
controls, thus excluding the diminutive effect of BMI on 25(OH)D concentration as the reason
for the lower vitamin D concentration in IBS. The lack of a diminutive effect of increasing
BMI on serum 25(OH)D in patients with IBS is interesting as this phenomenon has been
described only in children and adolescents with inflammatory bowel disease[6], but not in
pediatric patients with lactose intolerance[15] or in healthy subjects[15, 16].
The etiology of vitamin D deficiency in pediatric patients with IBS is not clear. It is likely
that the vitamin D deficiency described in our cohort resulted from a combination of limited
intake of vitamin D because of restricted dietary options and lifestyle habits that limit subjects’
exposure to sunlight[17–20]. A previous study described limited dietary food choices in
patients with IBS[17], with special emphasis on limited dairy intake[21], as well as deficiencies
in micronutrients such as iron, vitamin B12, and zinc[22]. This is in agreement with a recent
study showing significantly lower serum 25(OH)D concentration in vegans compared to meat
eaters[23].
Because IBS is functional disorder, the underlying mechanism for vitamin D deficiency
in this disorder is not known. Some of the postulated causes of vitamin D deficiency in
Fig 3. Graph of the relationship between the seasons and serum 25(OH)D concentration in patients
with IBS and controls. Serum 25(OH)D was significantly lower in the subjects with IBS compared to controls
(ANOVA, p = 0.04). Both groups had higher serum concentration of 25(OH)D in the summer compared to
winter (ANOVA, p = 0.04). There were no interactions between the groups and seasons (ANOVA, p = 0.24).
doi:10.1371/journal.pone.0172183.g003
Vitamin D status in irritable bowel syndrome
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gastrointestinal disorders include intestinal inflammation, dark skin pigmentation, insufficient
solar UV-B exposure, winter season, hypoalbuminemia, and secondary hyperparathyroidism
which accelerated the conversion of 25(OH)D to 1,25-dihydroxyvitamin D, thereby exhausting
the vitamin D stores[24]. The significantly lower serum albumin concentration in our IBS
cohort suggests that hypoalbuminemia may play a role in the pathogenesis of vitamin D defi-
ciency in IBS in children and adolescents. Vitamin D is transported in serum as vitamin D
binding protein and thus, low serum albumin concentration, could diminish vitamin D con-
centration. Serum albumin is a marker of both protein-losing enteropathy and liver function,
and has been proposed, along with ESR[6], as a primary determinant of vitamin D status in
inflammatory bowel disease[25, 26]. Recent advances in vitamin D research have reported
novel pathways of vitamin D metabolism[27–29] that challenge the classical pathway of vita-
min D metabolism from the photolysis of 7-dehydrocholesterol to form vitamin D3 and then
25(OH)D and 1,25-dihydroxyvitamin D. These non-classical pathways involve the generation
of intermediate precursors such as CYP11A1-derived secosteroids, and the initiation of novel
pathways of vitamin D3 metabolism by P450 side-chain cleavage enzyme and subsequent mod-
ification of the precursors by CYP27B1 enzyme system. It is unknown whether these pathways
are impaired in patients with IBS.
Fig 4. Box plot of the response of subjects with IBS to vitamin D supplementation. There was a significant rise in 25(OH)D
from baseline to 3 months, 45.4 ± 14.4 nmol/L to 68.8 ± 14.4 nmol/L, p = 0.002. This increase was sustained through the 9-month
observation, consistent with adequate absorption of ingested vitamin D.
doi:10.1371/journal.pone.0172183.g004
Vitamin D status in irritable bowel syndrome
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This study suggests that the non-dietary determinants of vitamin D in pediatric IBS include
hypoalbuminemia, dark skin pigmentation, winter seasons, and possibly the female sex. The
role of the female sex is important as 80% of the patients with IBS in our study is of the female
sex. Serum 25(OH)D was significantly higher in female controls compared to female IBS sub-
jects, but was similar between male controls and male IBS subjects. The racial disparities in 25
(OH)D concentration between the controls and subjects with IBS is related to differences in
UVB production of vitamin D[30].
Another novel finding from this study is that subjects with IBS and migraine have signifi-
cantly lower vitamin D level compared to the controls. Though the etiopathogenetic basis for
the co-occurrence of psychiatric and somatic symptoms in IBS is unknown[31], the high fre-
quency of the occurrence[32] of these disorders in IBS suggests a common etiological basis
that could be addressed with a unified therapeutic approach[2, 33]. Given that 80% of the IBS
cohort is of female sex, and that migraine occurs at a higher rate in females[34], it is possible
that migraine may occur at a higher frequency in female subjects with IBS and vitamin D defi-
ciency[35]. Serum 25(OH)D concentration was similar between the male and female subjects
with IBS in this study. More studies are needed to determine whether adjunctive vitamin D
therapy could improve the overall wellbeing of pediatric patients with IBS.
This study found no significant relationship between 25(OH)D and ALT, ESR, and albumin
after adjusting for confounders. This is an important area of comparison between IBS and
IBD. We have previously reported a significant inverse relationship between 25(OH)D and
ESR, but not for ALT and albumin, in children and adolescents with IBD[36]. It is possible
that the lack of a relationship between 25(OH)D and ESR in IBS is due to the functional nature
of IBS, in contrast to IBD which is primarily marked by intestinal inflammation[36]. The role
of inflammation on vitamin D status in IBD was noted in our previous study which showed a
significantly lower 25(OH)D concentration in IBD patients with elevated ESR compared to
controls[6]. The lack of a significant relationship between 25(OH)D and albumin in IBS is
similar to the findings of a study on albumin and 25(OH)D in inflammatory bowel disease
[37]; and the absence of a significant relationship between ALT and 25(OH)D in IBS is also
consistent with a report that characterized the relationship between vitamin D and liver
enzymes in adult patients with liver disease[38]. The seasonal variations in 25(OH)D in IBS
subjects is similar to the pattern described in published reports [36, 39, 40]. Equally, the signifi-
cantly elevated serum 25(OH)D concentration in NHW subjects is consistent with reports
from previous studies [41, 42].
This study has a number of limitations. First, the retrospective, cross-sectional design for
baseline comparisons limits causal inference on the effects of the studied parameters on vita-
min D status. However, the longitudinal analysis of vitamin D status following vitamin D sup-
plementation over 9 months suggests that vitamin D supplementation can improve and
maintain normal vitamin D status in children and adolescents with IBS. In this study, subjects
with IBS received either ergocalciferol or cholecalciferol. Recent studies suggest that the use of
cholecalciferol is more efficacious in raising and maintaining serum 25(OH)D concentration
[43–45]. The approach to the management of vitamin D deficiency in IBS is similar to the
established guidelines for the general population[12]. The second shortcoming of this study is
that food-recall questionnaires were not administered to the children to accurately determine
each subject’s dietary vitamin D intake. This is particularly important as vitamin D concentra-
tion may be diminished in patients with severe dietary restrictions, as well as in those with life-
style choices that limit sun exposure. Equally, there were no data on the consumption of
micronutrients as these may also be deficient in patients with IBS. Such data could have been
used to correlate the degree of vitamin D deficiency state to concomitant micronutrient defi-
ciency. Third, data on parathyroid hormone levels were not available as these could be elevated
Vitamin D status in irritable bowel syndrome
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in states of vitamin D deficiency. Fourth, this study was based on a small sample size and this
limits its generalizability. The IBS cohort was older than the controls, however, all relevant
analyses were adjusted for age and other covariates. Published studies showed that age has no
influence on vitamin D status[26]. The results of this study were not adjusted for the type of
medical therapy, or pubertal status, as earlier studies found no relationships between 25(OH)
D and these parameters in children and adolescents with gastrointestinal disorders [25, 39,
46].
The strengths of this study include its case-control design that allowed for the comparison
of key parameters in patients with IBS to similar parameters in the controls, thus providing an
objective reference point for the analysis. This study was conducted exclusively amongst sub-
jects residing in the same geographical latitude (42˚N) thus ensuring uniformity of exposure
to solar radiation. All subjects receiving vitamin D or calcium supplements were excluded
from the baseline analysis; and were only employed in the determination of the effect of vita-
min D supplementation on 25(OH)D concentration in IBS. Subjects’ anthropometric parame-
ters were expressed as z-score and all analyses were adjusted for confounders.
The importance of this study was to initiate the first steps in the critical assessment of the
role of vitamin D as an adjunctive therapy in children and adolescents with IBS. More studies
are needed to determine whether adequate vitamin D supplementation can improve the qual-
ity of life indices in these children and adolescents by decreasing the rate of symptom flares
and the occurrence of psychosomatic manifestations[2]. This hypothesis is supported by stud-
ies showing an association between psychiatric distress and hypovitaminosis D in youth[47],
the improvement of symptoms in youth with depression and other psychiatric illnesses who
received vitamin D supplementation[48–51], improvement in the quality of life of adult
patients with IBS who received vitamin D supplementation[2, 33, 52], and improved depres-
sive symptoms in youth with cystic fibrosis who received vitamin D supplementation[53].
Conclusions
In this study, pediatric patients with IBS had significantly lower 25(OH)D concentration com-
pared to controls despite having similar mean BMI values as controls. Only 7% of the children
and adolescents with IBS were vitamin D sufficient, and>50% of the subjects with IBS had
vitamin D deficiency. This is a much higher prevalence of vitamin D deficiency compared to
IBD and other malabsorption syndromes. This high prevalence of vitamin D deficiency in IBS
may due to a combination of factors such as restricted food choices, lifestyle habits that limit
exposure to sunshine, female sex, and the possible role of hypoalbuminemia. A close monitor-
ing of vitamin D status, and prompt repletion in cases of deficiency, should form part of
routine clinical care of patients with IBS. Large randomized control trials are warranted to
accurately determine the effect of optimal vitamin D supplementation on the intestinal and
extra-intestinal manifestations of IBS.
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